Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will resume the review of Theravance’s antibiotic telavancin at a three-day advisory committee meeting in November after completing an audit of the company’s clinical trial data.
You may also be interested in...
Guidance on Anti-Infective Non-Inferiority Margins May Not Be Clear-Cut
FDA is expected to provide some much-desired clarity on its policy for non-inferiority margins in clinical trials for anti-infectives at this week's advisory committee meeting. But the end result may not be the concrete answer that industry is hoping for
Guidance on Anti-Infective Non-Inferiority Margins May Not Be Clear-Cut
FDA is expected to provide some much-desired clarity on its policy for non-inferiority margins in clinical trials for anti-infectives at this week's advisory committee meeting. But the end result may not be the concrete answer that industry is hoping for
Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication
FDA advisory panel will review NDA that includes more safety data for the antibiotic than the European MAA did.